Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601. We show 31 historical shares outstanding datapoints in our GBT shares outstanding history coverage, used to compute GBT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GBT market cap history over the course of time is important for investors
interested in comparing GBT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GBT versus a peer is one thing; comparing
GBT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GBT can fluctuate over the course of history.
With this page we aim to empower investors researching GBT by allowing them to research the GBT market cap history. |
Free GBT Email Alerts:
Video: The Importance of Market Cap
